

August 30, 2017



# Navidea To Initiate Regular Webcast Series Featuring Moderated Q&A with Management

*First Webcast Scheduled with CFO for Tuesday, September 5, 2017 at 4:30pm ET*

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals (NYSE MKT: NAVB) (Navidea or The Company), a company focused on the development of precision immunodiagnostic agents and through its subsidiary Macrophage Therapeutics, immunotherapeutics, announced today that it will hold an Investor Relations (IR)-focused, online Question & Answer (Q&A) Session with Jed Latkin, Chief Financial and Chief Operating Officer of Navidea on Tuesday, September 5 at 4:30pm Eastern Time. Investors are invited to submit questions they would like to hear answered to [ir@navidea.com](mailto:ir@navidea.com) or [tpatel@edisongroup.com](mailto:tpatel@edisongroup.com) by Monday, September 4, 2017.

From time to time, between quarterly conference calls, the management will host Q&A webcasts so investors and potential investors can learn more about the Company, its strategy, and its products.

**Event:** Navidea IR Q&A Session – September 2017  
**Date:** Tuesday, September 5, 2017  
**Time:** 4:30pm ET  
**Webcast:** <http://www.audio-webcast.com/cgi-bin/visitors.ssp?fn=visitor&id=4973>

Navidea management plans to host Q&A sessions every other month, beginning with the first session on September 5, to field common or important questions its shareholders and potential investors have. This ongoing Q&A series will bring the Company ever closer to its shareholder base and is designed to maintain a continued open forum to highlight the Company's clinical trial progress as well as the many milestones Navidea hopes to achieve over the next several quarters.

For the September 5 IR-focused Q&A Session, Navidea invites all interested investors to submit questions they would like to see asked by Monday, September 4, 2017 to [ir@navidea.com](mailto:ir@navidea.com) or [tpatel@edisongroup.com](mailto:tpatel@edisongroup.com).

"Navidea is committed to driving shareholder value and we recognize that to succeed in the highly competitive pharmaceutical industry one must provide cutting edge technology and products. This requires focus and the ability to attract and retain world class scientists and innovators. The process is time consuming and never proceeds in a straight line and to insure existing and potential investors in the company have an opportunity to gain greater clarity on the prospects for Navidea we are initiating this effort. We anticipate that this format

will prove useful to investors and productive for our small management team,” commented Michael Goldberg, M.D., President and Chief Executive Officer of Navidea.

### **About Navidea Biopharmaceuticals**

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept™ platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc 99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. The development activities of the Manocept immunotherapeutic platform are being conducted by Navidea in conjunction with its subsidiary, Macrophage Therapeutics, Inc. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts.

For more information, please visit <http://www.navidea.com>.

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20170830006261/en/>

Navidea Biopharmaceuticals

Jed Latkin, CFO/COO, 614-973-7490

[jlatkin@navidea.com](mailto:jlatkin@navidea.com)

or

Edison Advisors

Tirth Patel, 646-653-7035

[tpatel@edisongroup.com](mailto:tpatel@edisongroup.com)

Source: Navidea Biopharmaceuticals, Inc.